Alembic Pharma Gains USFDA Approval for Tretinoin Cream

Alembic Pharmaceuticals Limited has received final approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Tretinoin Cream USP, 0.05%. The product, a generic version of the reference listed drug Retin-A Cream, is indicated for the topical treatment of acne vulgaris.

This latest regulatory clearance further strengthens Alembic’s presence in the U.S. dermatology market, a key segment for the company’s specialty generics strategy. According to data from market intelligence firm IQVIA, Tretinoin Cream (0.05%) held an estimated market size of approximately $76 million in the United States for the twelve-month period ending March 2026.

Strategic Expansion of U.S. Portfolio

The final approval for Tretinoin Cream is part of a broader acceleration in Alembic’s regulatory filings and product launches for the 2026 fiscal year. With this inclusion, the company has now accumulated a cumulative total of 242 ANDA approvals from the USFDA, consisting of 222 final approvals and 20 tentative approvals.

The company’s focus remains on expanding its regulated market footprint through complex generic launches, leveraging its vertically integrated research and development capabilities. The firm operates state-of-the-art manufacturing facilities that meet stringent regulatory standards, enabling it to maintain a consistent pipeline of drug approvals across various therapeutic categories.

Official Sources

In a regulatory filing submitted to the stock exchanges, Alembic Pharmaceuticals confirmed the receipt of the final USFDA approval. The company stated that the approved product is therapeutically equivalent to Bausch Health US, LLC’s Retin-A Cream, 0.05%. The filing aligns with the company’s standard disclosure practices under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Quote Section

"According to officials," the approval for Tretinoin Cream highlights the company’s sustained focus on building a robust portfolio in the U.S. generics market. Organizers stated that the product is prepared to move into the commercialization phase, following the standard post-approval internal processes.

Why It Matters

For investors and stakeholders, this approval marks another milestone in Alembic’s efforts to diversify its product base beyond basic generics into specialized therapeutic areas like dermatology. By securing market access for a high-demand product like Tretinoin Cream, the company reinforces its revenue potential in the U.S., a vital market that contributes significantly to its overall operational performance. The consistency of these approvals, following recent successes in oncology and neurology segments, positions the company as a reliable player in the competitive generic pharmaceutical landscape.

Key Facts at a Glance

• Product: Tretinoin Cream USP, 0.05% (Generic equivalent of Retin-A Cream).

• Indication: Topical treatment for acne vulgaris.

• Market Opportunity: Estimated $76 million (U.S. market, MAT March 2026).

• Regulatory Status: Final USFDA approval received.

• Alembic’s Milestone: Total cumulative USFDA ANDA approvals reach 242 (222 final, 20 tentative).

Frequently Asked Questions (FAQ)

What is Tretinoin Cream used for? Tretinoin Cream USP, 0.05%, is a topical medication primarily used for the treatment of acne vulgaris.

Is this a new product for Alembic Pharmaceuticals? Yes, it is the latest generic addition to the company’s dermatology portfolio in the United States, following the approval of other therapeutic products in the current fiscal year.

How many USFDA approvals does Alembic have now? With this approval, the company holds a cumulative total of 242 ANDA approvals from the U.S. health regulator.

Source: BSE Limited, Pharmabiz, Rediff Money